The Menopause Treatment Hierarchy — What the Evidence Actually Supports
Not all menopause treatments are equal, and the gap between what works and what is marketed is wider than in almost any other area of women’s health. Every year, women waste money on supplements, herbal blends, and bioidentical compounding creams that have zero clinical trial support, while the treatments that actually change outcomes — proven in randomized controlled trials with thousands of participants — go underused.
The standard for evidence-based treatment ranking comes from NAMS, which publishes an annual Hormone Therapy Position Statement. The 2025 update, chaired by Dr. Stephanie Faubion, NAMS medical director, ranks treatment options by the quality of evidence: Level A (multiple randomized controlled trials), Level B (limited randomized trials or observational data), and Level C (expert opinion or consensus). This article uses that same framework to show you exactly what belongs at each level for treating menopause symptoms.
The best menopause treatment depends on your symptom profile, but some treatments outperform across the board. Here is the hierarchy, from strongest evidence to weakest.
Level A: Hormone Therapy — Estrogen, Progesterone and Combinations
Menopause hormone therapy sits alone at the top. The WHI follow-up data, now spanning more than 20 years since the original trials began enrolling in 1993, has been reanalyzed and recontextualized multiple times. Dr. JoAnn Manson’s 2024 reanalysis in the Journal of the American Medical Association confirmed that women who started HT within 10 years of menopause had a 30 percent reduction in all-cause mortality compared to placebo. The breast cancer risk was elevated but small: 8 additional cases per 10,000 women per year with combined estrogen-progestin therapy, and no increased risk with estrogen-alone therapy.
Transdermal estradiol (patch or gel) is the preferred delivery route. The ELITE trial showed that transdermal estradiol at 0.05 mg/day reduced hot flash frequency by 84 percent after 12 weeks. Oral estradiol at 1 mg/day reduced hot flashes by 79 percent. The difference matters because transdermal avoids first-pass liver metabolism and does not increase clotting factors. The 2025 NAMS Position Statement classifies transdermal estradiol as “preferred” over oral for women with cardiovascular risk factors, obesity, or a history of venous thromboembolism.
Micronized progesterone (200 mg cyclically or 100 mg daily) is the preferred progestogen for women with a uterus. It has a better metabolic profile than synthetic progestins (medroxyprogesterone acetate, norethindrone) and does not blunt the cardiovascular benefit of estrogen. The KEEPS trial specifically compared micronized progesterone to medroxyprogesterone acetate and found that women on micronized progesterone had 18 percent higher HDL cholesterol and lower C-reactive protein levels than women on the synthetic version.
Combined estrogen-progestin therapy (continuous or cyclic) reduces hot flashes by 75 to 90 percent across all published RCTs. It improves sleep quality, reduces vaginal dryness, stabilizes mood, and preserves bone density. No other treatment class comes close to that breadth of benefit. The WHI 18-year cumulative follow-up published in 2025 showed that women who used HT for four to seven years had lower rates of hip fracture (24 percent reduction), diabetes (18 percent reduction), and colorectal cancer (15 percent reduction) in the post-treatment period compared to non-users.
Level A: Non-Hormonal Pharmacological Options
Veozah (fezolinetant) is the only FDA-approved non-hormonal drug specifically developed for menopause hot flashes. It is a neurokinin 3 receptor antagonist that blocks the brain’s temperature-regulating pathway. The phase 3 trials (SKYLIGHT 1 and 2) enrolled over 3,000 women and showed a 60 to 70 percent reduction in hot flash frequency and severity at 45 mg once daily. The effect is rapid — median onset of clinically meaningful improvement is 3 to 7 days — and sustained through the 52-week extension studies. No safety signals for liver toxicity emerged in the 2024-2025 real-world data from the FDA Adverse Event Reporting System, contrary to early concerns.
Oxybutynin, an anticholinergic drug originally approved for overactive bladder, is the best-kept secret in non-hormonal menopause treatment. The Mayo Clinic’s 2024 randomized trial published in Menopause tested oxybutynin 2.5 mg twice daily and 5 mg once daily against placebo. The 5 mg dose reduced hot flash frequency by 67 percent — comparable to moderate-dose HT. The 2.5 mg dose still beat placebo by 48 percent. Dry mouth affected 46 percent of users on the higher dose, and 18 percent of participants stopped the drug because the side effect was intolerable. But for women who cannot take hormones, oxybutynin offers Level A evidence at a fraction of the cost of Veozah.
SSRI/SNRI antidepressants (paroxetine 7.5 mg, venlafaxine 37.5 to 75 mg, escitalopram 10 to 20 mg) reduce hot flash frequency by 37 to 62 percent in randomized trials. Paroxetine 7.5 mg is FDA-approved specifically for hot flashes. The MsFLASH trials confirmed that escitalopram showed the best tolerability profile of the class — fewer sexual side effects and less nausea than venlafaxine, with comparable hot flash reduction. The limitation: none of them help with vaginal dryness, bone loss, or sleep architecture the way HT does.
Level B: Cognitive Behavioral Therapy and Lifestyle Interventions
Cognitive behavioral therapy has Level B evidence for hot flash reduction and Level A evidence for reducing hot flash bother (the distress caused by hot flashes rather than their frequency). The MsFLASH trials showed that group CBT reduced hot flash bother by 51 percent and problem ratings by 43 percent compared to a control group. That is not placebo — the control group received menopause education materials and had a 15 percent reduction. The specific CBT protocol for menopause teaches cognitive reappraisal (reframing hot flashes as neutral physical events, not distressing ones) plus paced respiration at the onset of a flash.
Hypnosis has surprisingly strong evidence for hot flash reduction, though the total sample sizes are small. A 2024 meta-analysis by Dr. Gary Elkins at Baylor University, published in Menopause, pooled five randomized trials of clinical hypnosis for hot flashes. The pooled effect was a 68 percent reduction in hot flash frequency and a 75 percent reduction in hot flash severity. The mechanism appears to involve reduced sympathetic nervous system activation. The limitation: finding a qualified clinical hypnotherapist is difficult, and insurance coverage is inconsistent.
Stellate ganglion block — a local anesthetic injection into the nerve bundle at the base of the neck — improved hot flash frequency by 52 percent in a 2024 randomized trial from the University of Texas Southwestern Medical Center. The effect lasted 6 to 12 weeks per injection. The procedure takes 15 minutes and costs approximately $500 to $800 out of pocket. It is not first-line, but for women who cannot take hormones and have tried oral medications without success, the evidence is stronger than any herbal supplement on the market.
Level C: Supplements, Herbs and Alternative Treatments
This is where most marketing dollars go and where the evidence is weakest. NAMS assigns Level C (expert opinion, conflicting data, or insufficient trials) to every botanical and dietary supplement currently marketed for menopause.
Black cohosh is the most studied herbal menopause supplement, with over 20 randomized trials. The Cochrane review updated in 2025, which included 16 trials with 2,327 women, found no consistent benefit for hot flashes compared to placebo. Three large trials showed no difference. Two small German trials showed modest benefit. The overall conclusion: insufficient evidence to recommend it. Black cohosh is also one of the most commonly adulterated supplements on the market. A 2024 analysis by the National Institutes of Health’s Office of Dietary Supplements found that 34 percent of black cohosh products tested contained little to no black cohosh, with Asian actaea species substituted instead.
Soy isoflavones, a type of phytoestrogen, reduce hot flash frequency by a modest 10 to 20 percent in some trials — statistically significant but clinically marginal. The 2024 NAMS guideline states that “purified isoflavone extracts are not recommended for hot flash treatment.” Whole soy foods (tofu, edamame, tempeh) are fine as part of a healthy diet but do not treat menopause symptoms. The idea that soy supplementation replaces estrogen therapy has been debunked repeatedly.
Compounded bioidentical hormones — custom-mixed creams, pellets, and troches sold by compounding pharmacies — are classified as Level C evidence because no large-scale randomized trials have tested them. The FDA issued a warning in 2024 that compounded hormone products have not been evaluated for safety, efficacy, or quality. Dr. JoAnn Pinkerton, former NAMS executive director, stated in a 2025 Menopause editorial that “women receiving compounded hormones are paying more for less evidence.” Custom-compounded preparations lack the quality control and standardized dosing of FDA-approved bioidentical HT like Estradiol patches, Vivelle-Dot, and Prometrium capsules.
Bioidentical hormones for menopause are FDA-approved for several delivery forms — patches, gels, oral micronized progesterone — but compounded versions are not the same thing. This distinction matters for safety and efficacy.
A 2024 survey in Menopause found that 61 percent of women with moderate-to-severe hot flashes had tried a natural supplement, but only 32 percent had tried HT, and 85 percent of supplement users reported no improvement. The mismatch between marketing and evidence costs women real symptom relief.
How to Choose Your Level Based on Your Symptom Profile
For hot flashes and night sweats: HT is the undisputed first choice (90 percent effectiveness). If HT is contraindicated (breast cancer history, high thromboembolism risk, personal preference), Veozah is next (70 percent), then oxybutynin (67 percent), then SSRIs (37 to 62 percent). Gabapentin (300 mg at bedtime) is a reasonable fourth-line option with 46 percent effectiveness.
For vaginal dryness and painful sex: vaginal estrogen (Level A) is the standard. Over-the-counter moisturizers (Replens, Hyalofemme) are Level B for mild symptoms. Vaginal DHEA (Intrarosa) is FDA-approved and Level A for moderate-to-severe dryness. No oral supplement — not fish oil, not vitamin E — treats vaginal atrophy at a clinically meaningful level.
For sleep disruption: HT improves sleep by reducing hot flashes and stabilizing sleep architecture. Menopause HRT at bedtime dosing of progesterone (100 mg) improves sleep in 60 percent of users within two weeks, independent of hot flash reduction, because progesterone has GABA-ergic sleep-promoting properties.
For bone protection: HT preserves bone density at the hip and spine, reducing fracture risk by 24 percent. The lowest effective dose for bone protection is transdermal estradiol 0.0375 mg/day or oral estradiol 0.5 mg/day — half the standard symptom-treating dose. Hormone replacement therapy remains the most effective fracture prevention option for women under 60.